Prosecution Insights
Last updated: April 19, 2026
Application No. 17/774,723

Method for Preparing Heteroleptic Triarylbismuthanes and Compounds Produced by the Same

Non-Final OA §103
Filed
May 05, 2022
Examiner
CHENG, KAREN
Art Unit
1623
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
UNIVERSITY OF HAWAII
OA Round
2 (Non-Final)
76%
Grant Probability
Favorable
2-3
OA Rounds
2y 3m
To Grant
99%
With Interview

Examiner Intelligence

Grants 76% — above average
76%
Career Allow Rate
517 granted / 677 resolved
+16.4% vs TC avg
Strong +28% interview lift
Without
With
+27.9%
Interview Lift
resolved cases with interview
Typical timeline
2y 3m
Avg Prosecution
34 currently pending
Career history
711
Total Applications
across all art units

Statute-Specific Performance

§101
1.0%
-39.0% vs TC avg
§103
27.4%
-12.6% vs TC avg
§102
21.5%
-18.5% vs TC avg
§112
30.7%
-9.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 677 resolved cases

Office Action

§103
DETAILED ACTION Claims 1-6 are currently pending in the instant application. Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Response to Arguments Applicant’s arguments, see p. 1-4, filed 12/15/2025, with respect to the rejection(s) of claim(s) 1-3 under Sharutin et al as well as claims 1-2, 4 and 6 under Furukawa et al have been fully considered and are persuasive. Therefore, the rejections have been withdrawn. However, upon further consideration, a new ground(s) of rejection is made in view of Sharutin et al. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. Claims 1-3 are rejected under 35 U.S.C. 103 as being unpatentable over Sharutin et al (see Russian Journal of General Chemistry, 2002, Vol. 72, No. 12, p. 1925-1926). Sharutin et al teach the reaction PNG media_image1.png 92 412 media_image1.png Greyscale and exemplifies adding pentaphenylantimony (2.17 mmol) and diphenyl-bismuth 4-methylbenzenesulfonate (2.17 mmol) to give triphenylbismuth. Although Sharutin et al does not teach a substoichimetric amount of the arylbismuth precursor relative to the nucleophile, it would have been prima facie obvious to vary the amount of bismuth compound to the antimony compound to optimize the yield of the process. According to MPEP 2144.05, Section II, differences in concentration or temperature will not support the patentability of subject matter encompassed by the prior art unless there is evidence indicating such concentration or temperature is critical. “[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation.” MPEP 2144.05 citing In re Aller, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955). Claims 1-2 and 5-6 are rejected under 35 U.S.C. 103 as being unpatentable over Barton et al (see Tetrahedron, 1986, Vol 42, No. 12, p. 3111-3122, see IDS filed 06/24/2022). Barton et al teach synthesis of di-p-tolylphenyl bismuth from di-p-tolylbismuth chloride (4.8 g = 11.2 mmol) and phenylmagnesium bromide from bromobenzene (1.76 g = 11.2 mmol) and magnesium (0.28 g = 11.5 mmol) - see p. 3119. Although Barton et al does not teach a substoichimetric amount of the arylbismuth precursor relative to the nucleophile, it would be obvious to vary the amount of bismuth compound to the nucleophile (i.e. phenylmagnesium bromide) to optimize the yield of the process. According to MPEP 2144.05, Section II, differences in concentration or temperature will not support the patentability of subject matter encompassed by the prior art unless there is evidence indicating such concentration or temperature is critical. “[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation.” MPEP 2144.05 citing In re Aller, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955). Claims 1-3 are rejected under 35 U.S.C. 103 as being unpatentable over Barton et al (see Tetrahedron, 1986, Vol 42, No. 12, p. 3111-3122, see IDS filed 06/24/2022) in view of Sharutin et al (see Russian Journal of General Chemistry, 2002, Vol. 72, No. 12, p. 1925-1926). The teachings of Sharutin et al are described in the above 103 rejection. Regarding the use of R2 as a tosyl group, Barton et al teach a chloro group instead. However Sharutin et al teaches that reaction of a diarylbismuth precursor having a tosyl group as a leaving group with an organometal nucleophile is known. Thus, a chloro and tosyl group would be considered equivalents as they both function as leaving groups and it would have been prima facie obvious to substitute one for the other. See MPEP 2144.06. Claims 1-2 and 5-6 are rejected under 35 U.S.C. 103 as being unpatentable over Gilman et al (see J. Am. Chem Soc, 1941, Vol. 63, No. 1, p. 207-211). Gilman et al teach the reaction diphenylbismuth chloride (0.01 mol) with α-naphthylmagnesium bromide (0.01 mol) to give diphenyl-α-naphthylbismuth. Although Gilman et al et al does not teach a substoichimetric amount of the arylbismuth precursor relative to the nucleophile, it would be obvious to vary the amount of bismuth compound to the nucleophile (i.e. α-naphthylmagnesium bromide) to optimize the yield of the process. According to MPEP 2144.05, Section II, differences in concentration or temperature will not support the patentability of subject matter encompassed by the prior art unless there is evidence indicating such concentration or temperature is critical. “[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation.” MPEP 2144.05 citing In re Aller, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955). Claims 1-3 are rejected under 35 U.S.C. 103 as being unpatentable over Gilman et al (see J. Am. Chem Soc, 1941, Vol. 63, No. 1, p. 207-211) in view of Sharutin et al (see Russian Journal of General Chemistry, 2002, Vol. 72, No. 12, p. 1925-1926). The teachings of Sharutin et al are described in the above 103 rejection. Regarding the use of R2 as a tosyl group, Gilman et al teach a chloro group instead. However Sharutin et al teaches that reaction of a diarylbismuth precursor having a tosyl group as a leaving group with an organometal nucleophile is known. Thus, a chloro and tosyl group would be considered equivalents as they both function as leaving groups and it would have been prima facie obvious to substitute one for the other. MPEP 2144.06. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to KAREN CHENG whose telephone number is (703)756-4699. The examiner can normally be reached M-F, 9AM-6PM PST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Adam Milligan can be reached at 571-270-7674. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /KAREN CHENG/Primary Examiner, Art Unit 1623 /ADAM C MILLIGAN/Supervisory Patent Examiner, Art Unit 1623
Read full office action

Prosecution Timeline

May 05, 2022
Application Filed
Sep 03, 2025
Non-Final Rejection — §103
Dec 15, 2025
Response Filed
Jan 08, 2026
Non-Final Rejection — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12595226
CARBONATE CONTAINING LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS
2y 5m to grant Granted Apr 07, 2026
Patent 12595266
PESTICIDALLY ACTIVE HETEROCYCLIC DERIVATIVES WITH SULFUR CONTAINING SUBSTITUENTS
2y 5m to grant Granted Apr 07, 2026
Patent 12583844
MATRIX METALLOPROTEINASE (MMP) INHIBITORS AND METHODS OF USE THEREOF
2y 5m to grant Granted Mar 24, 2026
Patent 12553889
SMALL MOLECULES TARGETING THE INTRINSICALLY DISORDERED STRUCTURAL ENSEMBLE OF ALPHA-SYNUCLEIN PROTECT AGAINST DIVERSE ALPHA-SYNUCLEIN MEDIATED DYSFUNCTIONS
2y 5m to grant Granted Feb 17, 2026
Patent 12552755
CINNAMIC AMIDE DERIVATIVE HAVING FXR ACTIVATING EFFECT, PHARMACEUTICAL COMPOSITION CONTAINING THE SAME AS ACTIVE INGREDIENT, AND METHOD FOR PREPARING THE SAME
2y 5m to grant Granted Feb 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

2-3
Expected OA Rounds
76%
Grant Probability
99%
With Interview (+27.9%)
2y 3m
Median Time to Grant
Moderate
PTA Risk
Based on 677 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month